IL160397A0 - Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 (1h) one derivatives for neurodegenerative disorders - Google Patents
Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 (1h) one derivatives for neurodegenerative disordersInfo
- Publication number
- IL160397A0 IL160397A0 IL16039702A IL16039702A IL160397A0 IL 160397 A0 IL160397 A0 IL 160397A0 IL 16039702 A IL16039702 A IL 16039702A IL 16039702 A IL16039702 A IL 16039702A IL 160397 A0 IL160397 A0 IL 160397A0
- Authority
- IL
- Israel
- Prior art keywords
- pyrimidin
- pyrimidinyl
- tetrahydropyrimido
- dihydroimidazo
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01402431A EP1295884A1 (en) | 2001-09-21 | 2001-09-21 | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives |
EP02290488A EP1340760A1 (en) | 2002-02-28 | 2002-02-28 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
PCT/EP2002/011127 WO2003027115A1 (en) | 2001-09-21 | 2002-09-19 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160397A0 true IL160397A0 (en) | 2004-07-25 |
Family
ID=26077255
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16039702A IL160397A0 (en) | 2001-09-21 | 2002-09-19 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 (1h) one derivatives for neurodegenerative disorders |
IL160397A IL160397A (en) | 2001-09-21 | 2004-02-15 | Substituted 2 - pyrimidinyl - 6,7,8,9 - tetrahydropyrimido {1,2-a} pyrimidin - 4 - one and 7 -pyrimidinyl - 2,3 - dihydroimidazo {1,2-a} pyrimidin - 5 (1h) one derivatives for neurodegenerative disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL160397A IL160397A (en) | 2001-09-21 | 2004-02-15 | Substituted 2 - pyrimidinyl - 6,7,8,9 - tetrahydropyrimido {1,2-a} pyrimidin - 4 - one and 7 -pyrimidinyl - 2,3 - dihydroimidazo {1,2-a} pyrimidin - 5 (1h) one derivatives for neurodegenerative disorders |
Country Status (24)
Country | Link |
---|---|
US (2) | US7388005B2 (xx) |
EP (1) | EP1430056B1 (xx) |
JP (2) | JP4570361B2 (xx) |
KR (1) | KR100868840B1 (xx) |
CN (1) | CN1247586C (xx) |
AR (1) | AR036599A1 (xx) |
AT (1) | ATE307815T1 (xx) |
AU (1) | AU2002342798C1 (xx) |
BR (1) | BR0212904A (xx) |
CA (1) | CA2457952C (xx) |
CY (1) | CY1105553T1 (xx) |
DE (1) | DE60206946T2 (xx) |
DK (1) | DK1430056T3 (xx) |
EA (2) | EA009456B1 (xx) |
ES (1) | ES2250721T3 (xx) |
HK (1) | HK1091495A1 (xx) |
HU (1) | HUP0500332A3 (xx) |
IL (2) | IL160397A0 (xx) |
MX (1) | MXPA04002632A (xx) |
NO (1) | NO329566B1 (xx) |
NZ (1) | NZ531244A (xx) |
PL (1) | PL370535A1 (xx) |
SI (1) | SI1430056T1 (xx) |
WO (1) | WO2003027115A1 (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1454909B1 (en) * | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
ATE393157T1 (de) | 2004-01-22 | 2008-05-15 | Amgen Inc | Substituierte heterocyclische verbindungen und anwendungsverfahren |
CN101198609A (zh) * | 2005-06-14 | 2008-06-11 | 先灵公司 | 天冬氨酰基蛋白酶抑制剂 |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP1939187A1 (en) * | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
EP1992624A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
EP1992621A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
EP1992620A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
EP1992625A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
EP2085400A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | Substituted heteroarylamide oxazepinopyrimidone derivatives |
EP2085399A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
EP2138498A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US8421890B2 (en) | 2010-01-15 | 2013-04-16 | Picofield Technologies, Inc. | Electronic imager using an impedance sensor grid array and method of making |
CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3865836A (en) * | 1972-12-08 | 1975-02-11 | Janssen Pharmaceutica Nv | Bicyclic imidazoles |
SU600143A1 (ru) * | 1976-12-06 | 1978-03-30 | Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср | Способ получени гетероциклических систем, содержащих бормзамещенный имидазол |
JPS63216886A (ja) * | 1987-03-05 | 1988-09-09 | Sumitomo Chem Co Ltd | ピリミドピリミジン誘導体およびその製造法 |
JP2862958B2 (ja) * | 1990-06-09 | 1999-03-03 | 三協化学株式会社 | 感熱転写記録用色素 |
US6153618A (en) * | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
IL130181A0 (en) * | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidone and pyridone compounds and methods of use |
NZ506417A (en) * | 1998-02-17 | 2003-05-30 | Tularik Inc | Anti-viral pyrimidine derivatives |
ATE303383T1 (de) * | 1999-12-17 | 2005-09-15 | Chiron Corp | Bizyklische inhibitoren von glycogen synthase kinase 3 |
FR2804959B1 (fr) | 2000-02-15 | 2006-04-28 | Centre Nat Rech Scient | Utilisation de derives de paullones pour la fabrication de medicaments |
-
2002
- 2002-09-19 AU AU2002342798A patent/AU2002342798C1/en not_active Ceased
- 2002-09-19 MX MXPA04002632A patent/MXPA04002632A/es active IP Right Grant
- 2002-09-19 IL IL16039702A patent/IL160397A0/xx unknown
- 2002-09-19 JP JP2003530703A patent/JP4570361B2/ja not_active Expired - Fee Related
- 2002-09-19 EA EA200600196A patent/EA009456B1/ru not_active IP Right Cessation
- 2002-09-19 CN CNB028183398A patent/CN1247586C/zh not_active Expired - Fee Related
- 2002-09-19 ES ES02779461T patent/ES2250721T3/es not_active Expired - Lifetime
- 2002-09-19 EA EA200400236A patent/EA007165B1/ru not_active IP Right Cessation
- 2002-09-19 PL PL02370535A patent/PL370535A1/xx unknown
- 2002-09-19 EP EP02779461A patent/EP1430056B1/en not_active Expired - Lifetime
- 2002-09-19 BR BR0212904-3A patent/BR0212904A/pt not_active Application Discontinuation
- 2002-09-19 NZ NZ531244A patent/NZ531244A/en not_active IP Right Cessation
- 2002-09-19 CA CA002457952A patent/CA2457952C/en not_active Expired - Fee Related
- 2002-09-19 KR KR1020047004138A patent/KR100868840B1/ko not_active IP Right Cessation
- 2002-09-19 US US10/490,136 patent/US7388005B2/en not_active Expired - Fee Related
- 2002-09-19 DE DE60206946T patent/DE60206946T2/de not_active Expired - Lifetime
- 2002-09-19 AT AT02779461T patent/ATE307815T1/de active
- 2002-09-19 WO PCT/EP2002/011127 patent/WO2003027115A1/en active IP Right Grant
- 2002-09-19 SI SI200230235T patent/SI1430056T1/sl unknown
- 2002-09-19 HU HU0500332A patent/HUP0500332A3/hu unknown
- 2002-09-19 DK DK02779461T patent/DK1430056T3/da active
- 2002-09-20 AR ARP020103540A patent/AR036599A1/es unknown
-
2004
- 2004-02-15 IL IL160397A patent/IL160397A/en not_active IP Right Cessation
- 2004-03-18 NO NO20041142A patent/NO329566B1/no not_active IP Right Cessation
-
2006
- 2006-01-09 CY CY20061100020T patent/CY1105553T1/el unknown
- 2006-11-21 HK HK06112764A patent/HK1091495A1/xx not_active IP Right Cessation
-
2008
- 2008-05-14 US US12/120,496 patent/US7781440B2/en not_active Expired - Fee Related
-
2010
- 2010-04-21 JP JP2010097989A patent/JP2010189422A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160397A0 (en) | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 (1h) one derivatives for neurodegenerative disorders | |
EP1599482A4 (en) | PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES | |
SI1430057T1 (sl) | Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati | |
IL170680A0 (en) | 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES | |
IL191960A (en) | History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them | |
PL377880A1 (pl) | Związki pirazolo [3,4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy | |
EP1454909B1 (en) | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases | |
AU1224902A (en) | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives | |
ZA200507192B (en) | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives | |
IL156536A0 (en) | Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same | |
AU2003255323A1 (en) | Imidazo`1,2-a!pyridines | |
IL175753A0 (en) | PROCESSES FOR THE PREPARATION OF PYRAZOLO [1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | |
SI1560830T1 (sl) | Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov | |
PL370565A1 (en) | 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists | |
PL370067A1 (en) | 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide | |
IL155379A0 (en) | SUBSTITUTED 3,4-DIHYDRO-PYRIMIDO[1,2-a] PYRIMIDINES AND 3,4-DIHYDROPYRAZINO [1,2-a] PYRIMIDINES | |
AU2002325550A1 (en) | (1,2,4)triazolo(1,5-a)pyrimidine derivative | |
AU2002219350A1 (en) | Pyrazolo(3,4-d)pyrimidine derivatives and their use as purinergic receptor antagonists | |
SI1325010T1 (en) | Substituted 3.4-dihydro-pyrimido (1,2-a)pyrimidines and 3.4-dihydropyrazino (1,2-a)pyrimidines | |
DK1325010T3 (da) | Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner | |
GB0312101D0 (en) | Use of pyrazolo[1,5-B]pyridazine derivatives for the treatment of psychiatric disorders |